JP2015514110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514110A5 JP2015514110A5 JP2015504677A JP2015504677A JP2015514110A5 JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5 JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- hla
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618969P | 2012-04-02 | 2012-04-02 | |
| US61/618,969 | 2012-04-02 | ||
| US201361778703P | 2013-03-13 | 2013-03-13 | |
| US61/778,703 | 2013-03-13 | ||
| PCT/US2013/034952 WO2013152001A2 (en) | 2012-04-02 | 2013-04-02 | Anti-hla-b*27 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514110A JP2015514110A (ja) | 2015-05-18 |
| JP2015514110A5 true JP2015514110A5 (enExample) | 2016-05-26 |
| JP6320993B2 JP6320993B2 (ja) | 2018-05-09 |
Family
ID=48093122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504677A Expired - Fee Related JP6320993B2 (ja) | 2012-04-02 | 2013-04-02 | 抗ｈｌａ−ｂ＊２７抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9790273B2 (enExample) |
| EP (1) | EP2834272B1 (enExample) |
| JP (1) | JP6320993B2 (enExample) |
| KR (1) | KR20150003256A (enExample) |
| CN (1) | CN104169302A (enExample) |
| AR (1) | AR090585A1 (enExample) |
| AU (1) | AU2013243644C1 (enExample) |
| BR (1) | BR112014024622A2 (enExample) |
| CA (1) | CA2868907C (enExample) |
| CL (1) | CL2014002631A1 (enExample) |
| CO (1) | CO7121320A2 (enExample) |
| EA (1) | EA201491827A1 (enExample) |
| HK (1) | HK1207092A1 (enExample) |
| IL (2) | IL234707A0 (enExample) |
| MX (1) | MX365690B (enExample) |
| MY (1) | MY171180A (enExample) |
| NZ (1) | NZ700650A (enExample) |
| PH (1) | PH12014502184A1 (enExample) |
| SG (2) | SG11201405759UA (enExample) |
| TW (1) | TWI619729B (enExample) |
| UY (1) | UY34721A (enExample) |
| WO (1) | WO2013152001A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20210074395A (ko) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CA2879577C (en) | 2012-07-27 | 2021-08-03 | City Of Hope | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| EA201791366A1 (ru) * | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| DK3253407T3 (da) * | 2015-02-04 | 2020-06-29 | Univ Zuerich | Brug af hla-b27-homodimere til kræftbehandling |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| CA2977106A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| CA2996299C (en) | 2015-08-24 | 2022-09-27 | University Of Cincinnati | Methods and compositions for the detection of fc receptor binding activity of antibodies |
| EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| CN108401431B (zh) * | 2015-12-18 | 2022-01-25 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| EA201891420A1 (ru) * | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CA3016752C (en) | 2016-03-08 | 2024-09-17 | Universitat Zurich | Hla-b57 open conformers |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| CA3031605A1 (en) | 2016-08-10 | 2018-02-15 | Universitat Zurich | Mhc class ia open conformers |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| CN110520145A (zh) * | 2017-03-31 | 2019-11-29 | 阿尔玛生物医疗公司 | Hla-b27相关炎性疾病的治疗方法及相关组合物 |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| EP4640703A3 (en) | 2017-11-14 | 2026-04-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
| MX2021001431A (es) | 2018-08-10 | 2021-05-12 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso. |
| JP2022525928A (ja) * | 2019-03-21 | 2022-05-20 | ガミダ セル リミテッド | 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用 |
| CA3137649A1 (en) | 2019-05-15 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
| CA3189755A1 (en) | 2020-07-25 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response |
| CN117321084A (zh) * | 2021-04-07 | 2023-12-29 | 雷杰纳荣制药公司 | 用于治疗mhc-1-病变的组合物 |
| WO2023064850A1 (en) * | 2021-10-14 | 2023-04-20 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
| WO2023220263A1 (en) * | 2022-05-13 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for modulating tcr |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340610C (en) * | 1985-08-16 | 1999-06-29 | Karen A. Nelson | Monoclonal antibody to polymorphic hla determinant-b27 |
| US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| WO2012047294A2 (en) * | 2010-10-06 | 2012-04-12 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja not_active Expired - Fee Related
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505125A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| SI3042917T1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| JP2018500014A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018021031A5 (enExample) | ||
| JP2016507470A5 (enExample) | ||
| JP2025131696A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2012523417A5 (enExample) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2015525795A5 (enExample) | ||
| JP2013542191A5 (enExample) | ||
| JP2023055904A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| JP2016519650A5 (enExample) | ||
| JP2018507220A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| JP2016513682A5 (enExample) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) |